CagriSema's mixed data lands at ADA 2026

At the American Diabetes Association's 86th Scientific Sessions (June 5–8, New Orleans), Novo Nordisk is presenting fresh analyses of CagriSema — its fixed-dose combination of the amylin analog cagrilintide and the GLP-1 drug semaglutide. The picture is genuinely mixed: CagriSema posts some of the strongest weight-loss numbers in the field on one hand, but missed a key head-to-head goal against tirzepatide on the other. The ADA data is part of Novo's effort to define where this amylin/GLP-1 combo fits in an increasingly crowded obesity market.

What happened

CagriSema pairs two appetite-regulating mechanisms — amylin agonism (cagrilintide) and GLP-1 agonism (semaglutide) — in one weekly injection. The data Novo is highlighting around ADA includes:

• REDEFINE 1 (vs placebo): a 22.7% mean weight reduction at 68 weeks versus 2.3% for placebo, in the analysis assuming full adherence (published in NEJM). A new ADA analysis reports 40.4% of adherent participants achieved ≥25% weight loss and 23.1% lost ≥30%.
• REDEFINE 4 (head-to-head vs tirzepatide): CagriSema produced 23.0% weight loss at 84 weeks versus 25.5% for tirzepatide 15 mg — and did not meet its primary endpoint of non-inferiority to tirzepatide.
• Type 2 diabetes data showed CagriSema outperforming semaglutide alone on weight in that population.

So the headline is two-sided: against placebo and in absolute terms, CagriSema's numbers are excellent; against the best-in-class competitor, it fell just short of its statistical goal. Novo has also filed for regulatory approval of the combination.

Why it matters

The cagrilintide half of CagriSema is the part most relevant to this site, because amylin is a distinct, peptide-based satiety mechanism we've covered on its own in cagrilintide for body composition and does cagrilintide cause muscle loss. CagriSema is the proof-of-concept that stacking amylin agonism with GLP-1 produces additive appetite suppression and large weight loss.

But the same caveat we apply across this whole class applies here, doubled by the magnitude of the loss: a 22–23% bodyweight reduction is enormous, and how much of it is fat versus muscle is the question the trials weren't built to answer. For lifters, the lesson from our tirzepatide muscle-loss coverage holds — protein and resistance training are what determine whether a loss that large preserves your hard-earned muscle. The REDEFINE 4 miss against tirzepatide is also a useful reality check: more mechanisms in the syringe don't automatically mean more weight loss, and the tirzepatide vs semaglutide hierarchy isn't easily overturned.

What to watch

At ADA, the detail worth tracking is tolerability and adherence — CagriSema's strongest numbers come from "if all adhered" analyses, and real-world adherence to a high-dose dual-agonist matters for the effect people actually get. Watch how Novo frames the REDEFINE 4 miss and whether the broader REDEFINE program (further trials are expected to read out into 2027) strengthens the case. And as always, keep an eye out for any body-composition sub-analysis that breaks the weight loss into fat and lean mass — the number that would actually tell a strength audience what these drugs cost in muscle.

Sources

• ADA: Novo continues effort to rehabilitate CagriSema — pharmaphorum
• CagriSema demonstrated 23% weight loss in head-to-head REDEFINE 4 trial; primary endpoint not achieved — Novo Nordisk